Detailed Study of the Hypertension - Pipeline Review, H1 2017

Hypertension - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Complete report available @ Hypertension - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 35, 35, 31, 89, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 11 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

A1M Pharma AB Actelion Ltd Alnylam Pharmaceuticals Inc Anacor Pharmaceuticals Inc AnGes MG Inc Arena Pharmaceuticals Inc Ascendis Pharma A/S Asklepion Pharmaceuticals LLC AVEO Pharmaceuticals Inc Bayer AG Bial - Portela & Ca SA Biolab Farmaceutica Ltda BioRestorative Therapies Inc Boryung Pharmaceutical Co Ltd Bristol-Myers Squibb Company Camurus AB Capricor Therapeutics Inc Celsion Corp Celtaxsys Inc Chiesi Farmaceutici SpA Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Conatus Pharmaceuticals Inc Corion Biotech Srl Cumberland Pharmaceuticals Inc Cytokinetics Inc Daewoong Co Ltd Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd DiaMedica Therapeutics Inc Eli Lilly and Company Esperion Therapeutics Inc F. Hoffmann-La Roche Ltd Ferring International Center SA Galectin Therapeutics Inc Gemphire Therapeutics Inc Gilead Sciences Inc GlaxoSmithKline Plc H. Lundbeck A/S HanAll Biopharma Co Ltd Hanmi Pharmaceuticals Co Ltd HitGen LTD Innopharmax Inc Insmed Inc Insys Therapeutics Inc Ionis Pharmaceuticals Inc Ironwood Pharmaceuticals Inc Jeil Pharmaceutical Co Ltd Johnson & Johnson JW Pharmaceutical Corp Kowa Company Ltd Leading BioSciences Inc Lee's Pharmaceutical Holdings Ltd Les Laboratoires Servier SAS LinXis BV Liquidia Technologies Inc Lotus Pharmaceutical Co Ltd MannKind Corp Marina Biotech Inc Merck & Co Inc Mezzion Pharma Co Ltd Mitsubishi Tanabe Pharma Corp Nanoform Cardiovascular Therapeutics Ltd Neurim Pharmaceuticals Ltd Nippon Kayaku Co Ltd Nippon Shinyaku Co Ltd Northern Therapeutics Inc Novartis AG Noxamet Ltd Omeros Corp Peloton Therapeutics Inc Pfizer Inc PhaseBio Pharmaceuticals Inc Pluristem Therapeutics Inc Polyphor Ltd Pulmokine Inc Quantum Genomics SA Reata Pharmaceuticals Inc RedHill Biopharma Ltd Relypsa Inc Renova Therapeutics Inc Respira Therapeutics Inc Reviva Pharmaceuticals Inc rEVO Biologics Inc Rottapharm Biotech Srl Sanofi Savara Inc Serodus ASA Shanghai Pharmaceutical Co Ltd Silence Therapeutics Plc Simcere Pharmaceutical Group SteadyMed Therapeutics Inc Suda Ltd Sumitomo Dainippon Pharma Co Ltd Sun Pharma Advanced Research Company Ltd Takeda Pharmaceutical Company Ltd The Medicines Company Theravance Biopharma Inc Toray Industries Inc Torrent Pharmaceuticals Ltd TSH Biopharm Corporation Ltd United Therapeutics Corp Vascular BioSciences Vectura Group Plc VG Life Sciences Inc Vicore Pharma AB Vivus Inc XORTX Pharma Corp XuanZhu Pharma Co Ltd Yuhan Corp

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###